169 related articles for article (PubMed ID: 31688416)
1. Prevalence of depression and anxiety in women newly diagnosed with vulvovaginal atrophy and dyspareunia.
Moyneur E; Dea K; Derogatis LR; Vekeman F; Dury AY; Labrie F
Menopause; 2020 Feb; 27(2):134-142. PubMed ID: 31688416
[TBL] [Abstract][Full Text] [Related]
2. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe.
DiBonaventura M; Luo X; Moffatt M; Bushmakin AG; Kumar M; Bobula J
J Womens Health (Larchmt); 2015 Sep; 24(9):713-22. PubMed ID: 26199981
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and Characteristics of Postpartum Vulvovaginal Atrophy and Lack of Association With Postpartum Dyspareunia.
Lev-Sagie A; Amsalem H; Gutman Y; Esh-Broder E; Daum H
J Low Genit Tract Dis; 2020 Oct; 24(4):411-416. PubMed ID: 32569019
[TBL] [Abstract][Full Text] [Related]
4. Biopsychosocial predictors of postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal atrophy, cognitive-emotional factors, and dyadic adjustment.
Kao A; Binik YM; Amsel R; Funaro D; Leroux N; Khalifé S
J Sex Med; 2012 Aug; 9(8):2066-76. PubMed ID: 22621792
[TBL] [Abstract][Full Text] [Related]
5. The effect of vulvovaginal atrophy on women's quality of life from an Italian cohort of the EVES study.
Nappi RE; Di Carlo C; Becorpi AM; Gambacciani M; De Seta F; Ribaldone R; Benedetto C; Paoletti AM;
J Obstet Gynaecol; 2020 May; 40(4):512-519. PubMed ID: 31496326
[TBL] [Abstract][Full Text] [Related]
6. [Sulphurous vaginal douching and vulvovaginal atrophy].
Costantino M; Conti V; Marongiu MB; Napolano G; Filippelli A
Clin Ter; 2017; 168(5):e300-e306. PubMed ID: 29044352
[TBL] [Abstract][Full Text] [Related]
7. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study.
Salvatore S; Nappi RE; Zerbinati N; Calligaro A; Ferrero S; Origoni M; Candiani M; Leone Roberti Maggiore U
Climacteric; 2014 Aug; 17(4):363-9. PubMed ID: 24605832
[TBL] [Abstract][Full Text] [Related]
8. Comorbidities Among Women With Vulvovaginal Complaints in Family Practice.
Leusink P; Kaptheijns A; Laan E; van Boven K; Lagro-Janssen A
J Sex Med; 2016 Feb; 13(2):220-5. PubMed ID: 26782608
[TBL] [Abstract][Full Text] [Related]
9. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study.
Palma F; Volpe A; Villa P; Cagnacci A;
Maturitas; 2016 Jan; 83():40-4. PubMed ID: 26421474
[TBL] [Abstract][Full Text] [Related]
10. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
Archer DF
J Steroid Biochem Mol Biol; 2015 Jan; 145():139-43. PubMed ID: 25201455
[TBL] [Abstract][Full Text] [Related]
11. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
12. Vulvovaginal symptoms prevalence in postmenopausal women and relationship to other menopausal symptoms and pelvic floor disorders.
Erekson EA; Li FY; Martin DK; Fried TR
Menopause; 2016 Apr; 23(4):368-75. PubMed ID: 26645820
[TBL] [Abstract][Full Text] [Related]
13. Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy.
Constantine GD; Bruyniks N; Princic N; Huse D; Palmer L; Lenhart G; Blumentals WA; Nappi RE
Curr Med Res Opin; 2014 Jan; 30(1):143-8. PubMed ID: 24083677
[TBL] [Abstract][Full Text] [Related]
14. Fractional CO
Siliquini GP; Tuninetti V; Bounous VE; Bert F; Biglia N
Climacteric; 2017 Aug; 20(4):379-384. PubMed ID: 28503946
[TBL] [Abstract][Full Text] [Related]
15. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study.
Nappi RE; Seracchioli R; Salvatore S; Cagnacci A; Di Paolantonio T; Busacca M;
Gynecol Endocrinol; 2019 May; 35(5):453-459. PubMed ID: 30700188
[TBL] [Abstract][Full Text] [Related]
16. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
Bachmann GA; Komi JO;
Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
[TBL] [Abstract][Full Text] [Related]
17. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety.
Vicariotto F; DE Seta F; Faoro V; Raichi M
Minerva Ginecol; 2017 Aug; 69(4):342-349. PubMed ID: 28608667
[TBL] [Abstract][Full Text] [Related]
18. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach.
Ettinger B; Hait H; Reape KZ; Shu H
Menopause; 2008; 15(5):885-9. PubMed ID: 18779677
[TBL] [Abstract][Full Text] [Related]
19. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
McLendon AN; Clinard VB; Woodis CB
Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
[TBL] [Abstract][Full Text] [Related]
20. Vulvovaginal atrophy in women after cancer.
Cox P; Panay N
Climacteric; 2019 Dec; 22(6):565-571. PubMed ID: 31411904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
